| Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ... Journal for immunotherapy of cancer 6, 1-15, 2018 | 91 | 2018 |
| Kinetic modelling of central carbon metabolism in Escherichia coli K Peskov, E Mogilevskaya, O Demin The FEBS journal 279 (18), 3374-3385, 2012 | 79 | 2012 |
| Agent based modeling of human gut microbiome interactions and perturbations T Shashkova, A Popenko, A Tyakht, K Peskov, Y Kosinsky, L Bogolubsky, ... PLoS One 11 (2), e0148386, 2016 | 54 | 2016 |
| DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results NM Gizzatkulov, II Goryanin, EA Metelkin, EA Mogilevskaya, KV Peskov, ... BMC systems biology 4, 1-11, 2010 | 54 | 2010 |
| Quantitative systems pharmacology: an exemplar model‐building workflow with applications in cardiovascular, metabolic, and oncology drug development G Helmlinger, V Sokolov, K Peskov, KM Hallow, Y Kosinsky, V Voronova, ... CPT: pharmacometrics & systems pharmacology 8 (6), 380-395, 2019 | 47 | 2019 |
| A physiology-based model of bile acid distribution and metabolism under healthy and pathologic conditions in human beings V Voronova, V Sokolov, A Al-Khaifi, S Straniero, C Kumar, K Peskov, ... Cellular and Molecular Gastroenterology and Hepatology 10 (1), 149-170, 2020 | 38 | 2020 |
| Quantitative mechanistic modeling in support of pharmacological therapeutics development in immuno-oncology K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger Frontiers in immunology 10, 450826, 2019 | 34 | 2019 |
| Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 … T Yakovleva, V Sokolov, L Chu, W Tang, PJ Greasley, H Peilot Sjögren, ... Diabetes, Obesity and Metabolism 21 (12), 2684-2693, 2019 | 32 | 2019 |
| Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis B Shulgin, Y Kosinsky, A Omelchenko, L Chu, G Mugundu, S Aksenov, ... Oncoimmunology 9 (1), 1748982, 2020 | 30 | 2020 |
| Differentiating the sodium‐glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling V Sokolov, T Yakovleva, L Chu, W Tang, PJ Greasley, S Johansson, ... CPT: Pharmacometrics & Systems Pharmacology 9 (4), 222-229, 2020 | 29 | 2020 |
| Drug-disease modeling in the pharmaceutical industry-where mechanistic systems pharmacology and statistical pharmacometrics meet G Helmlinger, N Al-Huniti, S Aksenov, K Peskov, KM Hallow, L Chu, ... European Journal of Pharmaceutical Sciences 109, S39-S46, 2017 | 26 | 2017 |
| Kinetic modeling as a tool to integrate multilevel dynamic experimental data E Mogilevskaya, N Bagrova, T Plyusnina, N Gizzatkulov, E Metelkin, ... Protein Networks and Pathway Analysis, 197-218, 2009 | 24 | 2009 |
| KINETIC MODEL OF PHOSPHOFRUCTOKINASE-1 FROM ESCHERICHIA COLI K Peskov, I Goryanin, O Demin Journal of bioinformatics and computational biology 6 (04), 843-867, 2008 | 19 | 2008 |
| Longitudinal tumor size and neutrophil‐to‐lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non‐small cell lung cancer treated with … S Gavrilov, K Zhudenkov, G Helmlinger, J Dunyak, K Peskov, S Aksenov CPT: pharmacometrics & systems pharmacology 10 (1), 67-74, 2021 | 18 | 2021 |
| Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia [S] V Sokolov, G Helmlinger, C Nilsson, K Zhudenkov, S Skrtic, B Hamrén, ... Journal of Lipid Research 60 (9), 1610-1621, 2019 | 18 | 2019 |
| Role of T cell-to-dendritic cell chemoattraction in T cell priming initiation in the lymph node: an agent-based modeling study I Azarov, K Peskov, G Helmlinger, Y Kosinsky Frontiers in immunology 10, 443009, 2019 | 17 | 2019 |
| Applications of model-based meta-analysis in drug development P Chan, K Peskov, X Song Pharmaceutical research 39 (8), 1761-1777, 2022 | 16 | 2022 |
| Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization? V Voronova, K Zhudenkov, G Helmlinger, K Peskov PLoS One 12 (2), e0171781, 2017 | 16 | 2017 |
| Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance V Voronova, A Vislobokova, K Mutig, M Samsonov, K Peskov, ... Frontiers in Oncology 12, 1035884, 2022 | 13 | 2022 |
| Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model V Voronova, K Peskov, Y Kosinsky, G Helmlinger, L Chu, A Borodovsky, ... Frontiers in Immunology 12, 617316, 2021 | 10 | 2021 |
